Burnaby, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) — Qu Biologics Inc. develops Site Specific Immunomodulators (SSI), a new immunotherapy platform designed to restore congenital immune function. A private clinical stage biopharmacy company. Qu’s team expansion, the start of three additional Phase 2 clinical trials, and the end of US $ 12 million equity financing to enable acceleration of Qu’s new immunomodulatory platform.
Hal Gunn, MD, CEO of QuBiologics, said: Two of these important trials are in critical indications for which there is no effective treatment. Innate immunity decline in the elderly and postoperative innate immunosuppression. “
“We strategically advance the expansion of our scientific, manufacturing, and clinical teams, recover safely, and through processes that include innate immune training and tissue-specific targeting of activated immune cells, the essentials of the innate immune system. In contrast to other immune therapies that seek to target one cell or receptor, SSI therapy is the innate immunity that the body needs to overcome and cure the condition. We use multiple elements of the to direct, “says Dr. Shirin Kalyan (PhD), VP Scientific Innovation of Qu. “Given the widespread application of our SSI platform, this funding will allow Qu Biologics to provide important and breakthrough treatments for people with cancer, infectious diseases and chronic inflammatory diseases,” said Dr. Gunn. One step closer to. “
For more information on the science behind Qu Biologics and SSI, please visit: www.qubiologics.com..
Qu Biologics designed to restore the congenital immune function of target organs to reverse the immune dysregulation that underlies many important diseases such as cancer, inflammatory bowel disease, infectious diseases, and inflammatory diseases. A clinical stage biotechnology company that develops a new class of immunotherapy, site-specific immunomodulators (SSI). Lung disease. Qu has completed four phase II trials for lung cancer, Crohn’s disease, and ulcerative colitis. Qu’s Phase 5 Phase 2 trial is ongoing for colon cancer, with four additional Phase 2 randomized placebo-controlled trials planned for congenital immunity of the elderly, colon cancer, pancreatic cancer, and lung cancer. It has been.
Backed by a group of prestigious scientific advisors and board members, QuBiologics is headed by management, including co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic diseases. Dr. Simon Sutcliffe, Chief Executive Officer, is a former CEO of the BC Cancer Agency and a prominent clinician, scientist and leader in cancer management in Canada and internationally. For more information, please visit www.qubiologics.com.
Qu Biologics Inc. warns that any non-explanatory statement of historical facts contained in this press release may be a forward-looking statement. Forward-looking statements are only forecasts based on current expectations and involve known and unknown risks and uncertainties. Unless otherwise stated, please be careful not to place undue reliance on these forward-looking statements that are mentioned only as of the date of publication of the relevant information. Actual results, performance, or outcomes may differ materially from those expressed or implied in Qu Biologics’ forward-looking statements due to the risks and uncertainties inherent in Qu Biologics’ business. .. This includes, but is not limited to, statements about: Its clinical trials; difficulties or delays in development, testing, regulatory approval, product manufacturing and marketing. Unexpected adverse side effects or inadequate therapeutic effects of a product that may delay or hinder the development or commercialization of the product. The scope and effectiveness of the patent protection of the product. Competing with other pharmaceutical or biotechnology companies. And the ability to raise additional funding to support its operation. Qu Biologics undertakes no obligation to update any forward-looking statement, except as required by law.
CBJ News Maker
QuBiologics Ends US $ 12 Million Equity Finance, Canadian Business Journal
Source link QuBiologics Ends US $ 12 Million Equity Finance, Canadian Business Journal